CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG
3.2.1. Patented products
3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS
3.5.1. Top factors impacting Malaysia IVIG market
3.5.2. Top investment pockets
3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS
3.7.1. Primary activities
3.7.2. Support activities
3.8. PRODUCT SCENARIO IN IVIG MARKET
3.9. GOVERNMENT REGULATIONS AND REIMBURSEMENTS
3.10. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. MARKET DYNAMICS
3.11.1. Drivers
3.11.1.1. Rise in number of immunodeficiency diseases
3.11.1.2. Increase in adoption of IVIG
3.11.1.3. Increase in number of people with bleeding disorders
3.11.1.4. Rise in aging population
3.11.2. Restraints
3.11.2.1. Stringent regulations
3.11.2.2. High cost of IVIG therapy
3.11.3. Opportunities
3.11.3.1. Untapped potential of Malaysia as an emerging economy
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4 MALAYSIA IVIG MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)
4.3.1. Market size and forecast
4.4. IMMUNODEFICIENCY DISEASES (ID)
4.4.1. Market size and forecast
4.5. MYASTHENIA GRAVIS (MG)
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY (MMN)
4.6.1. Market size and forecast
4.7. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES (IM)
4.8.1. Market size and forecast
4.9. SPECIFIC ANTIBODY DEFICIENCY (SAD)
4.9.1. Market size and forecast
4.10. GUILLAIN-BARR SYNDROME (GBS)
4.10.1. Market size and forecast
4.11. KAWASAKI DISEASE (KD)
4.11.1. Market size and forecast
4.12. SECONDARY IMMUNE DEFICIENCY (SID)
4.12.1. Market size and forecast
4.13. OTHERS
4.13.1. Market size and forecast
CHAPTER 5 MALAYSIA IVIG MARKET, BY PRODUCT
5.1. OVERVIEW
5.2. IGG
5.2.1. Key market trends
5.2.2. Clinical interpretations
5.3. IGA
5.3.1. Key market trends
5.3.2. Clinical interpretations
5.4. IGM
5.4.1. Key market trends
5.4.2. Clinical interpretations
5.5. IGE
5.5.1. Key market trends
5.5.2. Clinical interpretations
5.6. IGD
5.6.1. Key market trends
5.6.2. Clinical interpretations
CHAPTER 6 MALAYSIA IVIG MARKET, BY MODE OF DELIVERY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Market size and forecast
6.4. INTRAMUSCULAR MODE OF DELIVERY
6.4.1. Market size and forecast
CHAPTER 7 MALAYSIA IVIG MARKET, BY CONCENTRATION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. 5% CONCENTRATION
7.2.1. Market size and forecast
7.3. 10% CONCENTRATION
7.3.1. Market size and forecast
7.4. OTHER CONCENTRATIONS
7.4.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. BAXTER INTERNATIONAL INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BIOTEST AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. CSL LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GREEN CROSS CORPORATION
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GRIFOLS S.A.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. JOHNSON & JOHNSON
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. KEDRION S.P.A.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. OCTAPHARMA AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. SHIRE PLC
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments